Schizophrenia clinical trials
160 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
- A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- 52-week Open Label Safety-Tolerability Study
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
- Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
- Synbiotic Compound to Reduce Symptoms of Schizophrenia
- Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
- Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
- Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
- Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Deep Brain Stimulation for Psychosis
- A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Acetazolamide for Treatment Resistant Schizophrenia
- Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls
- Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
- Cognitive Training for Emotion Regulation in Psychotic Disorders
- Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
- A Study of Brenipatide in Adult Participants With Schizophrenia
- Effectiveness of Motivation Skills Training (MST)
- NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
- Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- A Study to Evaluate the Effect of KarXT on Urological Safety
- A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
- NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
- Randomized Withdrawal Study in Patients With Schizophrenia
- An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- Tolerability of MDMA in Schizophrenia
- Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Study of ALTO-101 in Patients With Schizophrenia
- A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
- Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
- Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)
- Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
- Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
- A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
- A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
- Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
- Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Schizophrenia” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.